Abstract

Multiple endocrine neoplasia type 1 (MEN-1) is a rare autosomal-dominant disease. It is associated with a broad range of endocrine tumours, most frequently arising in the parathyroid glands, the pituitary and the pancreas. Most neuroendocrine tumours will be diagnosed in the pancreas as non-functioning neuroendocrine tumours or insulinomas. Forty-two percent of the patients will develop a gastrin-secreting neuroendocrine tumour, a gastrinoma. Gastrinomas in MEN-1 tend to be small, multiple and preferentially located in the duodenum. This paper will focus on the specific characteristics of gastrinomas in the setting of MEN-1 compared to sporadic gastrinomas. The developments in understanding the tumorigenesis of these tumours and the consequences for diagnosis and therapy will be discussed.

Highlights

  • Multiple endocrine neoplasia type 1 (MEN-1) is a rare autosomal-dominant disease

  • In patients with Zollinger-Ellison syndrome with MEN-1 and hypercalcaemia omeprazole 40 mg b.i.d. or equivalent is recommended as a staring dose and followed by a reduction to 20 mg b.i.d. if possible

  • It has been demonstrated recently that gastrinomas associated with MEN-1 are preferentially located in the duodenum, arise from gastrin cell hyperplasia, so-called precursor lesions that develop to micro-tumours after loss of heterozygosity

Read more

Summary

Introduction

Multiple endocrine neoplasia type 1 (MEN-1) is a rare autosomal-dominant disease. MEN-1 is associated with a broad range of endocrine tumours, most frequently arising in the parathyroid glands, the pituitary and the pancreas. Penetrance for neuroendocrine tumours is up to 70%–100%. Half of the patients with MEN-1 will present with a pancreatico-duodenal neuroendocrine tumour at the age of 50 years. Most will arise in the pancreas as non-functioning neuroendocrine tumours or insulinomas. In contrast to sporadic gastrinomas that occur predominantly in the pancreas, in MEN-1 most of these tumours reside in the duodenum [1]. Pancreatic gastrinomas associated with MEN-1 are very rare [2], as are other uncommon extra-pancreatic, extra-duodenal locations that have been associated with gastrinomas

Pathogenesis and Classification
Clinical Presentation
Biochemical Diagnosis
Tumour Localisation
Medical Treatment of Acid Hypersecretion
Surgical Therapy of the Gastrinoma
Treatment of Metastasized Gastrinoma
Gastric Neuroendocrine Tumours Type 2
Findings
Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call